201 research outputs found
Kinetics of neuroendocrine differentiation in an androgen-dependent human prostate xenograft model
Population pharmacokinetics of vancomycin in obesity: Finding the optimal dose for (morbidly) obese individuals
Aims: For vancomycin treatment in obese patients, there is no consensus on the optimal dose that will lead to the pharmacodynamic target (area under the curve 400–700 mg h L−1). This prospective study quantifies vancomycin pharmacokinetics in morbidly obese and nonobese individuals, in order to guide vancomycin dosing in the obese. Methods: Morbidly obese individuals (n = 20) undergoing bariatric surgery and nonobese healthy volunteers (n = 8; total body weight [TBW] 60.0–234.6 kg) received a single vancomycin dose (obese: 12.5 mg kg−1, maximum 2500 mg; nonobese: 1000 mg) with plasma concentrations measured over 48 h (11–13 samples per individual). Modelling, internal validation, external validation using previously published data and simulations (n = 10.000 individuals, TBW 60–230 kg) were performed using NONMEM. Results: In a 3-compartment model, peripheral volume of distribution and clearance increased with TBW (both p  90% target attainment (area under the curve > 400 mg h L−1) in individuals up to 200 kg, with corresponding trough concentrations of 5.7–14.6 mg L−1 (twice daily dosing). For continuous infusion, a loading dose of 1500 mg is required for s
Tobramycin Clearance Is Best Described by Renal Function Estimates in Obese and Non-obese Individuals: Results of a Prospective Rich Sampling Pharmacokinetic Study
Purpose Tobramycin is an aminoglycoside antibiotic of
which the 24 h exposure correlates with efficacy. Recently,
we found that clearance of the aminoglycoside gentamicin
correlates with total body weight (TBW). In this study, we
investigate the full pharmacokinetic profile of tobramycin in
obese and non-obese individuals with normal renal function.
Methods Morbidly obese individuals (n = 20) undergoing
bariatric surgery and non-obese healthy volunteers (n = 8),
with TBW ranging 57–194 kg, received an IV dose of
tobramycin with plasma concentrations measured over 24 h
(n = 10 per individual). Statistical analysis, modelling and simulations were performed using NONMEM.
Results In a two-compartment model, TBW was the best predictor for central volume of distribution (p< 0.001). For clearance,
MDRD (de-indexed for body surface area) was identified as best
covariate (p < 0.001), and was superior over TBW ((p < 0.05).
Other renal function estimates (24 h urine GFR and de-indexed
CKD-EPI) led to similar results as MDRD (all p < 0.001)).
Conclusions In obese and non-obese individuals with normal
renal function, renal function estimates such as MDRD were
identified as best predictors f
- …